Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Mobius Therapeutics™ Receives Payment Indicator for Reimbursement of Mitosol®Reimbursement to Compounded Medication Excluded Under this Code
“This is a substantial milestone and confirms the inherent value represented by Mitosol®,” said Ed Timm, President of Mobius Therapeutics. “In light of the on-going concerns related to the sterility and quality assurance of compounded medications, this will give providers and patients peace of mind, knowing that the precision, safety, and convenience of Mitosol® is also the wise economic choice.” J-codes are part of the Health Common Procedure Coding System (HCPCS) and are used by providers to identify drugs and facilitate their reimbursement. These codes are acknowledged by Medicare and most private insurance carriers. “This further validates the inherent value of FDA approved formulations versus compounded medications,” About Mobius Therapeutics, LLC: Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|